Cargando…
JAK-STAT in lymphoproliferative disorders
Autores principales: | Rabadan, Raul, Inghirami, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606001/ https://www.ncbi.nlm.nih.gov/pubmed/26501073 |
Ejemplares similares
-
The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019) -
Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders
por: Butzmann, Alexandra, et al.
Publicado: (2022) -
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017) -
JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020) -
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)